Harpoon Therapeutics to Participate in 33rd Annual Roth Conference
09 mars 2021 07h30 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Corporate Update
04 mars 2021 07h30 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics to Participate in SVB Leerink Global Healthcare Conference
17 févr. 2021 07h30 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics Granted Orphan Drug Designation from FDA for HPN217 for Treatment of Multiple Myeloma
13 janv. 2021 07h30 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics Announces Closing of Public Offering of Common Stock
11 janv. 2021 16h01 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP) announced today the closing of its underwritten public offering of 6,764,704 shares of its...
Harpoon Therapeutics Announces Pricing of Public Offering of Common Stock
06 janv. 2021 21h44 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), announced today the pricing of an underwritten public offering of 5,882,352 shares of its...
Harpoon Therapeutics Announces Proposed Public Offering of Common Stock
06 janv. 2021 16h01 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers,...
Harpoon Therapeutics Reports Clinical Progress Across All Four TriTAC® Pipeline Development Programs
08 déc. 2020 08h00 HE
|
Harpoon Therapeutics
HPN424 has shown confirmed partial response in treatment of metastatic castration-resistant prostate cancer in highest fixed dose cohort (160 ng/kg) of continuing Phase 1/2a dose escalation trial ...
Harpoon Therapeutics to Host Clinical Pipeline Programs Update Call and Webcast on December 8, 2020
07 déc. 2020 16h05 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...
Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences
09 nov. 2020 07h30 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today...